Catenin Beta 1 drugs in development by Therapy Areas, Indications, Stages, MoA, RoA, Molecule Type, and Key Players, 2023

The report also covers products from therapy areas such as Oncology, Respiratory, Dermatology, and Non Malignant Disorders which include the indications Colorectal Cancer, Solid Tumor, Idiopathic Pulmonary Fibrosis, Scar, and Hemangiomas. It also reviews key players involved in Catenin Beta 1 targeted therapeutics development with respective active and dormant or discontinued products.

The Catenin Beta 1 pipeline targets constitutes close to 23 molecules. Out of which, approximately 17 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, Preclinical, and Discovery stages are 3, 1, 5, and 8 respectively. Similarly, the universities portfolio in Phase I, Preclinical, and Discovery comprises 1, 2, and 3 molecule.

Catenin Beta 1 overview

Catenin beta-1 or β-catenin is a protein that is encoded by the CTNNB1 gene. In the presence of Wnt ligand, CTNNB1 acts as a coactivator for transcription factors of the TCF/LEF family, leading to activate Wnt responsive genes. It is involved in the regulation of cell adhesion, CDK2/PTPN6/CTNNB1/CEACAM1 pathway of insulin internalization. It also acts as a negative regulator of centrosome cohesion. It blocks anoikis of malignant kidney and intestinal epithelial cells and promotes their anchorage-independent growth by down-regulating DAPK2.

For a complete picture of Catenin Beta 1’s drug pipeline, buy the report here.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.

Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.